CONMED因Airseal一次性购买数据和关税而在Stifel降级

2025-04-29 00:53

Stifel has downgraded CONMED (NYSE:CNMD) to hold from buy citing Q1 hospital purchasing data on Airseal disposables as a key factor.
The investment bank also cut its price target to $55 from $75 (~8% upside based on April 25 close).
Analyst Rick Wise noted that the data indicates the quarter was the first time Airseal sales declined year over year since 2020.
He added that uncertainty over tariffs and the economy are weighing on CONMED, as well as "the company's back-end weighted 2025 guidance."
"Thus, until we get a clearer sense that the macro issues are
going to be less of a concern and that the insufflation data is going to turn more positive, we feel compelled to move to the sidelines as we await greater clarity on the company’s strategic operational, and Airseal-offsetting priorities," Wise wrote.

More on CONMED